Videos Library

Event Videos

PharmAccess Leaders Forum (Autumn)

Berlin, Germany - September 27-29, 2016

Biosimilar, but different: Establishing (or defending) value through multi-criteria decision analytic (MCDA) modelling

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR, Biosimilars
Availability: FREE
  • How the complex characteristics of biologics (and biosimilars) contribute to perceived value to different stakeholders.
  • The salient issues facing upstarts (marketers of biosimilars) and defenders (marketers of “original” biologics) in communicating comparative worth to stakeholders.
  • How MCDA modelling methods can assist both groups in better defining and communicating value.

Mason W. Russell
MAPE, Vice President
Truven Health Analytics, USA


Cell & gene therapies: A global perspective of HTA, funding & reimbursement challenges

Related topics: Pharmaceutical/Biotech, Market Access & HEOR, Global (non-specific)
Availability: FREE
  • Overview of cell & gene therapies.
  • Health technology assessment & cost effectiveness challenges.
  • Who pays? Healthcare system determinants of funding / reimbursement.
  • Affordability: Pricing and budget impact challenges.
  • Lessons learned: Early case studies.

Neil Palmer
President & Principal Consultant
PDCI Market Access Inc.


Leveraging RWE to support market access: Lessons learned

Related topics: Pharmaceutical/Biotech, Europe, Market Access & HEOR, Real-World Evidence & Late-Phase Research
Availability: FREE

Market access is value contextual, thus using RWE to secure appropriate market access allows evidence to reflect effectiveness in the real world where protocols may not be followed, patients don’t take their medications, and where every population is viewed as unique requiring data to reflect that specific population . This presentation walks through the reality of developing RWE for an EUmarketed, post-anaesthesia medication using a retrospective observational study format and demonstrates the importance of thinking carefully about your strategy (the benefits, risks, costs and mitigations) before embarking.


Mervyn D. Hall
Director of Market Access – Europe
Truven Health Analytics, UK